IP Library › Granted Patent US 12,357,593
Granted Patent B2
US 12,357,593 · App. 18/462,648 · Granted Jul 15, 2025

Ovarian cancer vaccines

Inventors: Vincent K. Tuohy (Broadview Heights, OH); Suparna Mazumder (Olmsted Falls, OH); Justin M. Johnson (Willoughby Hills, OH)
Assignee: The Cleveland Clinic Foundation
A61K31/138A61K31/337A61K31/4196A61K31/4745A61K31/4985A61K31/502A61K31/555A61K31/675A61K31/704A61K31/7048A61K31/7064A61K31/7068A61K33/243A61K39/001102A61K40/11A61K40/13A61K40/24A61K40/4202A61K45/06A61P35/00A61K33/244A61K2039/575A61K2239/59
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,593
App. No.
18/462,648
Granted
Jul 15, 2025
Kind
B2
Abstract

Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).

Claims (20)

1. A method of eliciting an AMHR2-specific immune response in a female human subject comprising: administering to the subject an immunogenic composition comprising a nucleic acid encoding an Anti-Mullerian Hormone Receptor, Type II (AMHR2) polypeptide,

wherein the AMHR2 polypeptide comprises the extracellular domain of human AMHR2, wherein the immunogenic composition elicits an immune response specific for an AMHR2 polypeptide comprising the extracellular domain of human AMHR2.

2. The method of claim 1 , wherein the nucleic acid encoding the AMHR2 polypeptide is an expression vector encoding the AMHR2 polypeptide.

3. The method of claim 1 , wherein the nucleic acid encoding the AMHR2 polypeptide comprises an mRNA encoding the AMHR2 polypeptide.

4. The method of claim 1 , wherein the nucleic acid encoding the AMHR 2 polypeptide is operably incorporated into a delivery vector.

5. The method of claim 4 wherein the delivery vector is selected from biodegradable microcapsules, immune-stimulating complexes, and liposomes.

6. The method of claim 5 , wherein the delivery vector is a viral vector.

7. The method of claim 6 , wherein the viral vector is an adenovirus, an adeno-associated virus, a vaccinia virus, or a baculovirus.

8. The method of claim 1 , wherein the immunogenic composition comprises an adjuvant.

9. The method of claim 8 , wherein the adjuvant is selected from:

Adjuvant 65, α-GalCer, aluminum phosphate, aluminum hydroxide, calcium phosphate, β-Glucan Peptide, CpG DNA, GM-CSF, GPI-0100, IFA, IFN-γ, IL-17, lipid A, lipopolysaccharide, Lipovant, Montanide, N-acety 1-muramy 1-L-alany 1-D-isoglutamine, Pam3CSK4, poly-IC, quil A, trehalose dimycolate and zymosan.

10. The method of claim 8 , wherein the adjuvant comprises aluminum.

11. The method of claim 8 , wherein the adjuvant is one that induces a mixed type I/type 17 immune response.

12. The method of claim 1 , further comprising a step of determining whether the subject comprises an ovarian cancer tumor that expresses AMHR2.

13. The method of claim 1 , wherein the female human subject comprises a BRCA1 or BRCA2 mutation in their genome.

14. The method of claim 1 , wherein the female human subject has a family history of ovarian cancer.

15. A method comprising vaccinating a female human subject with a vaccine comprising an immunogenic composition comprising a human Anti-Mullerian Hormone Receptor, Type II (AMHR2) extracellular domain polypeptide or a human AMHR2 cytoplasmic domain polypeptide.

16. A method comprising vaccinating a female human subject with a vaccine comprising an immunogenic composition comprising a nucleic acid encoding a human Anti-Mullerian Hormone Receptor, Type II (AMHR2) extracellular domain polypeptide or a nucleic acid encoding a human AMHR2 cytoplasmic domain polypeptide.

17. The method of claim 15 , wherein the immunogenic composition comprises a human Anti-Mullerian Hormone Receptor, Type II (AMHR2) extracellular domain polypeptide.

18. The method of claim 16 , wherein the immunogenic composition comprises a nucleic acid encoding a human Anti-Mullerian Hormone Receptor, Type II (AMHR2) extracellular domain polypeptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2024
From: TUOHY, VINCENT K.; MAZUMDER, SUPARNA; JOHNSON, JUSTIN M.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 067690/0612 →
CONFIRMATORY LICENSE Recorded Jan 29, 2024
From: CLEVELAND CLINIC FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066377/0513 →
Continuity (4)
Continuation 17404025 · Aug 17, 2021
Continuation 15757151
Provisional Application 62213286 · Sep 2, 2015
Related Publication 20240041798A1 · Feb 8, 2024
References Cited (47)
US 11090284B2 · Tuohy · 2021 [cited by examiner]
US 11786489B2 · Tuohy · 2023 [cited by examiner]
US 20150004156A1 · Gaucher et al. · 2015 [cited by applicant]
JP 2004521609 · 2004 [cited by applicant]
JP 2005533488 · 2005 [cited by applicant]
JP 2014517685 · 2014 [cited by applicant]
JP 2015506341 · 2015 [cited by applicant]
JP 2015516374 · 2015 [cited by applicant]
WO WO2002012341 · 2002 [cited by applicant]
WO WO2003080835 · 2003 [cited by applicant]
WO WO2005005615 · 2005 [cited by applicant]
WO WO2012140627 · 2012 [cited by applicant]
WO WO2013136182 · 2013 [cited by applicant]
WO WO2014153636 · 2014 [cited by applicant]
WO WO2015114142 · 2015 [cited by applicant]
Gouédard et al (JBC, 2000, 275(36): 27973-27978). [cited by examiner]
Chowdhury et al (Journal of Immunological Methods, 2001, 249: 147-154). [cited by examiner]
Weide et al (Immunology Letters, 2008, 115: 33-42). [cited by examiner]
Alipour et al., Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy. Oct. 2016; 8(10):1193-204. [cited by applicant]
Bookman et al., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the G… [cited by applicant]
Bos et al., Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen. Cancer Res. 2008;68(20):8446-55. [cited by applicant]
Genbank Accession No. AKI72055.1, Jun. 1, 2015, 2 pages. [cited by applicant]
Genbank Accession No. NM_020547.2, Oct. 7, 2016, 4 pages. [cited by applicant]
Genbank Accession No. NM_001164690.1, Oct. 6, 2016, 4 pages. [cited by applicant]
Genbank Accession No. NP_065434, Apr. 9, 2021, 3 pages. [cited by applicant]
Genbank Accession No. NP_001158163.1, Apr. 9, 2021, 3 pages. [cited by applicant]
Genbank Accession No. NP_001158162, Apr. 10, 2021, 3 pages. [cited by applicant]
Gonzalez-Exposito et al., CEA Expression Heterogeneity and Plasticity Confer Resistance to the CEA_Targeting Bispecific Immunotherapy Antibody Cibisatamab (CEA-TCB) in Patient-Derived Colorectal Cancer Orgnoids. J Immun… [cited by applicant]
Kandalaft et al., Immunotherapy for ovarian cancer: what's next? J Clin Oncol. Mar. 1, 2011;29(7):925-33. [cited by applicant]
Kersual et al., The human Mullerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer: Validation using mAb12G4. MAbs. 2014;6(5):1314-26. [cited by applicant]
King et al., GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med. May 10, 2010;207(5):953-61. [cited by applicant]
Kohlgraf et al., Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother. Dec. 2004;53(12):1068-84. [cited by applicant]
Mazumder et al., Immunotherapy of Ovarian Cancer with a Monoclonal Antibody Specific for the Extracellular Domain of Anti-Mullerian Hormone Receptor II. Oncotarget. May 19, 2020;11(20)1894-1910. [cited by applicant]
Mellman et al., Cancer immunotherapy comes of age. Nature. Dec. 21, 2011;480(7378):480-9. [cited by applicant]
Odunsi et al., NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. Sep. 15, 2003;63(18):6076-83. [cited by applicant]
Pardoll, Cancer Vaccines. Immunology Today. Jun. 1993;14(6):310-6. [cited by applicant]
Rosen et al., Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. Nov. 2005;99(2):267-77. [cited by applicant]
Sakalar et al., Regulation of murine ovarian epithelial carcinoma by vaccination against the cytoplasmic domain of anti-Mullerian hormone receptor II. J Immunol Res. 2015;2015:630287. [cited by applicant]
Samanci et al., Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with reco… [cited by applicant]
Turriziani et al., Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials. Recent Patents on Anti-Cancer Drug Discovery. May 18, 2012;7(3)2… [cited by applicant]
Ulanova et al., The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun. Feb. 2001;69(2):1151-9. [cited by applicant]
Ullenhag et al., Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA. Cancer Immunol Immunother. Apr. 2004;53(4):331-7. [cited by applicant]
Visser et al., Structure and chromosomal localization of the human anti-müllerian hormone type II receptor gene. Biochem Biophys Res Commun. Oct. 24, 1995;215(3):1029-36. [cited by applicant]
Zhang et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. Jan. 16, 2003;348(3):203-13. [cited by applicant]
International Search Report and Written Opinion for International Patent Application PCT/US2016/050159, mailed Dec. 8, 2016, 13 pages. [cited by applicant]
Kantor, et al., “ [cited by applicant]
Lin, et al., “ [cited by applicant]